Фармакотерапия нарушений функций ЦНС в гинекологической практике как проблема коррекции расстройств адаптации

С. Г. Бурчинский

doi:10.18370/2309-4117.2016.28.52-55

Authors

С. Г. Бурчинский SI “Gerontology Institute named after D.F. Chebotarev of the NAMS of Ukraine”, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2016.28.52-55

Keywords:

menopause, premenstrual dysphoric syndrome, insomnia, melatonin, vita-melatonin

Abstract

Currently, in the developed countries 30–45% of the population suffering from sleep disorders or insomnia, which indicates a high prevalence and social significance of the insomnia problem. At menopause syndrome and premenstrual dysphoric syndrome insomnia occur in 60–80% of cases, significantly affecting the psychological state and quality of women’s life, causing formation of the neurotic, cerebrovascular, cardiac and other diseases. This is largely due to the development of circadian rhythm disorders are closely associated with neuroendocrine factors.

Sleep hormone melatonin is a major factor for humoral regulation of sleep-wake cycle, and one of the key factors determining the adaptive capacity of the central nervous system and the whole organism. As a natural chronobiotic synchronizing circadian biorhythms, melatonin provides a normalization of various aspects of the central nervous system, derived from the equilibrium state. In clinical practice this is reflected in the presence of hypnogenic effect of melatonin, which serves as a basis for leading the clinical indications for its use – insomnia of different nature.

Melatonin is characterized by the combined chronotropic, anxiolytic, antidepressant and cognitive effects are not peculiar to any other neuro- and psychotropic drugs.

In many clinical studies melatonin confirmed the efficacy and safety as a hypnotic, adaptogen and control functions of the central nervous system. Melatonin provides sleep as close to reality as possible. Melatonin is characterized by a high safety level, a complete lack of postsomnic syndrome and psychomotor disorders, as well as the risk of addiction and dependence. In patients with insomnia during treatment with melatonin there were reduction of emotional lability, anxiety, depression, improve mood, increase clarity of consciousness, short-term memory improvement, reducing fatigue, increasing social activity.

Among the melatonin preparations present in Ukraine, special attention should be paid for drug vita-melatonin, which fully complies with all international quality standards and the most economically accessible.

Author Biography

С. Г. Бурчинский, SI “Gerontology Institute named after D.F. Chebotarev of the NAMS of Ukraine”

PhD, head of Information аnalysis and Іnternational scientific programs Department

References

Avedisova, A.S. “Hypnotics: the achievements of modern psychopharmacology.” Journal of Neurology, Psychiatry 103.1 (2003): 51–53.
Arushanyan, E.B. “Epiphyseal hormone melatonin in combined pharmacotherapy of brain disorders and somatic pathology.” Experimental Clinical Pharmacology 74.9 (2011): 39–45.
Arushanyan, E.B., Beyer, E.V. “Melatonin, the hormone of a brain gland epiphysis is a universal natural adaptogen.” Advances of Physiological Sciences 43.2 (2012): 82–100.
Burchynskyi, S.G. “Sleep disorders in depression, new opportunities of antidepressants.” Ukrainian Neurological Journal 2 (2012): 84–89.
Diukova, G.M. “Quality of life in women during menopause.” Treating Physician 1 (2001): 3–6.
Korkushko, O.V., Shatylo, V.B., Pisaruk, A.V., et al. “Biorhythms, melatonin and aging.” Journal of practitioners 1 (2004): 38–43.
Kochetkov, Y.A. “Melatonin and depression.” Journal of Neurology, Psychiatry 107.6 (2007): 79–83.
Povorozniuk, V.V., Grygorieva, N.V. Menopause and musculoskeletal system. Kyiv (2004): 511 p.
Auersperg, K.T. “Sleep disorders during female life cycle.” Ann Rev Neurogeriatr 6 (2012): 74–88.
Becker-Andre, M., Wiesenberg, J., Schaeren-Wilmers, N., et al. “Pineal hormone melatonin binds and activates an orphan pf the nuclear receptor superfamily.” J Biol Chem 269 (1994): 28531–4.
Cardinali, D.P., Srinivasan, V., Brzecinsky, A., et al. “Melatonin and its analogs in insomnia and depression.” J Pineal Res 52 (2012): 365–75.
Connoly, M. “Premenstrual syndrome.” Adv Psychiat Treat 7 (2001): 469–77.
Dolberg, O.T., Hirshmann, S., Grunhaus, L. “Melatonin for the treatment of sleep disturbances in major depressive disorder.” Amer J Psychiat 155 (1998): 1119–21.
Karakas, A., Coskun, H., Kaya, A., et al. “The effect of intraamygdalar melatonin injections on the anxiety like behaviour and the spatial memory performance in male Wistar rats.” Behav Brain Res 222 (2011): 141–50.
Klein, D.C., Moore, R.Y., Reppert, S.M. Suprachiasmatic Nucleus: The Minds Clock. New York. Univ. Press (1991): 225 p.
Kryger, M.N., Roth, T., Dement, W.C. Principles and practice of sleep medicine. W.B. Saunders & Co (1994): 386 p.
Pandi-Perumal, S.R., Zisapel, N., Srinivasan, V., et al. “Melatonin and slee[ in aging population.” Exp Gerontol 40 (2005): 911–25.
Rehman, H.U., Masson, E.A. “Neuroendocrinology of female aging.” Gend Med 2 (2005): 41–56.
Wirz-Justice, A. “Circadian disturbances in depression: therapeutic perspectives.” Medicographia 25 (2003): 29–36.
Wyatt, J.K., Dijk, D.J., Ritz-de Cecco, A., et al. “Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent.” Sleep 29 (2006): 609–18.